PDF(Pubmed)
Abstract：
The expression of EGFR and p16 in the external auditory canal squamous cell carcinoma (EACSCC) and their impacts on oncological outcomes were not well studied. Seventeen-one consecutive patients who were treated for EACSCC at Kobe University Hospital from 1995 to 2018 were enrolled in this study. The expression of EGFR, and p16 were evaluated and their impacts on oncological outcomes were statistically analyzed. Positive expression of EGFR was observed in 62 patients (87%). Strong positive expression of p16 were observed in 18 patients (32.4%), and weakly positive expression in 30 patients (42.3%), respectively. While the number of the patients with negative EGFR expression were limited, all the surgically treated patients with negative EGFR expression have been alive without disease. In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.
摘要：
EGFR和p16在外耳道鳞状细胞癌（EACSCC）中的表达及其对肿瘤预后的影响尚未得到很好的研究。这项研究纳入了1995年至2018年在神户大学医院接受EACSCC治疗的17名连续患者。EGFR的表达,对p16和p16进行评估,并对其对肿瘤结局的影响进行统计学分析.EGFR阳性表达62例(87%)。18例(32.4%)患者p16蛋白表达呈强阳性,30例(42.3%)患者呈弱阳性表达,分别。虽然EGFR表达阴性的患者数量有限，所有接受手术治疗的EGFR表达阴性的患者均无疾病存活.在T3和T4aEACSCC患者中，p16表达阳性的EACSCC患者的预后趋于优于p16表达阴性的患者。这些结果表明EGFR和p16表达在晚期EACSCC患者中预测肿瘤预后的临床意义。
